Jiewen Deng

Dr. Jiewen Deng


Research Focus & Metrics

Academic Career Length

5Years (2022-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
5 May 2022 in Materials
Verified
Journal Article
Open access
PDF file
JDJiewen Deng
Jiewen Deng
YXYAO XIE
YAO XIE
JSJian Shen
Jian Shen
QGQing Gao
Qing Gao
JHJing He
Jing He
MXMeixiang Xiang
Meixiang Xiang
Dendritic cells (DCs) are recognized as the most effective antigen-presenting cells at present. DCs have corresponding therapeutic effects in tumor immunity, transplantation immunity, infection inflammation and cardiovascular diseases, and the activation of T cells is dependent on DCs. However, normal bone-marrow-derived Dendritic cells (BMDCs) cultured on conventional culture plates are easy to be activated during culturing, and it is difficult to imitate the internal immune function. Here, we reported a novel BMDCs culturing with hydrogel substrate (CCHS), where we synthesized low substituted Gelatin Methacrylate-30 (GelMA-30) hydrogels and used them as a substitute for conventional culture plates in the culture and induction of BMDCs in vitro. The results showed that 5% GelMA-30 substrate was the best culture condition for BMDCs culturing. The low level of costimulatory molecules and the level of development-related transcription factors of BMDCs by CCHS were closer to that of spleen DCs and were capable of better promoting T cell activation and exerting an immune effect. CCHS was helpful to study the transformation of DCs from initial state to activated state, which contributes to the development of DC-T cell immunotherapy.

13 March 2024 in International Immunopharmacology
Verified
Journal Article
Closed access
WWWei Wan
Wei Wan
XQXinyu Qian
Xinyu Qian
BZBole Zhou
Bole Zhou
JGJie Gao
Jie Gao
JDJiewen Deng
Jiewen Deng
DZDongbao Zhao
Dongbao Zhao